Abstract: The invention relates to an isolated interleukin-17 (IL-17)-binding agent which comprises an immunoglobulin heavy chain polypeptide comprising SEQ ID NO: 1, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 78, or SEQ ID NO: 79, and an immunoglobulin light chain polypeptide comprising SEQ ID NO: 23, except that one or more specific of residues of SEQ ID NO: 1 and SEQ ID NO: 23 are replaced with a different residue. The invention also provides vectors, compositions, and methods of using the IL-17-binding agent to treat an IL-17-mediated disease.

Abstract: The disclosure relates to an isolated IL-17-binding agent which comprises an immunoglobulin heavy chain polypeptide comprising SEQ ID NO: 1 and optionally an immunoglobulin light chain polypeptide comprising SEQ ID NO: 23, except that one or more specific of residues of SEQ ID NO: 1 and SEQ ID NO: 23 are replaced with a different residue. The disclosure also provides vectors, compositions, and methods of using the IL-17-binding agent to treat an IL-17-mediated disease.

Abstract: The invention is directed to a method of preparing a nucleic acid sequence with a modified splice site usage profile, which employs the use of a nucleic acid sequence comprising a cryptic splice donor site. The invention also provides a method of producing an alternate form of an RNA molecule encoded by a nucleic acid sequence, which nucleic acid sequence comprises a cryptic splice donor site, a heterologous nucleic acid sequence, and a splice acceptor site.

Abstract: The invention relates to a method of identifying a desired antigen-binding agent that binds to an antigen of interest. The method utilizes a combinatorial approach wherein a nucleic acid sequence encoding a polypeptide comprising a first component of an antigen-binding agent is provided to a population of cells together with a library of nucleic acid sequences, each of which encodes a polypeptide comprising a second component of an antigen-binding agent. The method further comprises subjecting one or more of the nucleic acid sequences encoding a first component, a second component, and/or an identified antigen-binding agent to somatic hypermutation.

Abstract: A chemical genus of 2-(aminomethyl)arylamides, which are useful as analgesics, is disclosed.

Abstract: Methods for identifying modulators of receptor activity using orthologues of human receptors are described. Additionally, a method for identifying an animal model useful in the screening of potential therapeutic agents is provided. The genes for bradykinin B1 receptors from five mammalian species, vervet monkey, rhesus macaque, tree shrew, dog and pig, as well as the genes for CXCR2 receptors from chimpanzee, gorilla, orangutan, rhesus, vervet and baboon have been cloned and characterized and are described herein.

Abstract: A chemical genus of 2-(aminomethyl)arylamides, which are useful as analgesics, is disclosed.

Abstract: Methods for identifying modulators of receptor activity using orthologues of human receptors are described. Additionally, a method for identifying an animal model useful in the screening of potential therapeutic agents is provided. The genes for bradykinin B1 receptors from five mammalian species, vervet monkey, rhesus macaque, tree shrew, dog and pig, as well as the genes for CXCR2 receptors from chimpanzee, gorilla, orangutan, rhesus, vervet and baboon have been cloned and characterized and are described herein.

Abstract: The genes for bradykinin B1 receptor from five mammalian species, vervet monkey, rhesus macaque, tree shrew, dog and pig have been cloned and characterized. In addition to the delineation of the nucleotide and amino acid sequences, methods for identifying modulators of bradykinin B1 receptor activity using these molecules is also described. Additionally, a method for identifying an animal model useful in the screening of potential therapeutic agents is provided.